3 TOP ASX Growth Stocks From 2021: Year In Review (BRN, LKE, IMU)
3 TOP ASX Growth Stocks from 2021 were Brainchip (ASX: BRN), Lake Resources (ASX: LKE) & Imugene (ASX: IMU).
Today we unpack these 3 ASX Growth Stocks that had great success in 2021 with a range of ASX Growth Stocks garnering significant interest for ASX investors with companies like Brainchip (BRN), Lake Resources (LKE) and Imugene (IMU).
The following ASX Growth Stocks are featured in today’s episode as stocks to watch on the ASX in 2022 after a successful 2021.
Brainchip (ASX: BRN) have developed their Akida technology which is the world’s first neuromorphic processor with Akida leveraging SNN (Spiking Neural Networks) to deliver A.I at the edge. Brainchip (BRN) have begun commercialisation of Akida and have recently attracted a lot of ASX investors interest with BRN’s share price climbing on excitement about their Akida semiconductor chip. Brainchip (BRN) is an exciting ASX Semiconductor stock and this ASX Technology company has been attracting ASX investor interest with some leading global partnerships with Renesas and Megachips for Brainchip’s Akida IP technology in the semiconductor space.
Lake Resources (ASX: LKE) are attracting significant ASX investor interest as a potential leading ASX Lithium stock a unique DLE (Direct Lithium Extraction) method. LKE have recently announced further developments for their Kachi Lithium project with a potential resource expansion for Kachi as they move towards a DFS. Lake Resources (LKE) have continued on a stellar start to 2021 with this innovative ASX Lithium growth stock focusing on riding the waves of Electric Vehicle (EV) adoption and providing Lithium from their Kachi Lithium project located in the Lithium triangle leveraging DLE.
Imugene (ASX: IMU) are a leading ASX biotech stock and attracted ASX Investor interest after announcing an official partnership with leading global big pharma players Pfizer and Merck Germany for their HER-Vaxx immunotherapy treatment. Imugene have continued on a stellar start to 2021 with this innovative ASX Biotech immunotherapy company riding the tailwinds of their innovative immunotherapy platforms including HERVaxx, CHECKVacc, PD1Vaxx and onCARlytics.
In today’s episode we unpack the growth stories behind each of the ASX Growth Stocks (BRN, LKE & IMU) and discuss where Brainchip (ASX: BRN), Lake Resources (ASX: LKE) & Imugene (ASX: IMU) may head after a successful 2021 with the ASX in 2022 providing a fascinating platform for these ASX Growth Stocks that are exciting ASX investors.
The following timestamps have been included to guide your viewing experience:
00:00 - Welcome
01:10 – Lake Resources (ASX: LKE)
06:32 – Imugene (ASX: IMU)
09:50 – Brainchip (ASX: BRN)
#Brainchip #Imugene #LakeResources
-------------------------------------------------------------------------------
✔️ Join the Community: / @asxinvestor
Twitter: / asxinvest
Discord Link: / discord
-------------------------------------------------------------------------------
Disclaimer:
I am not a financial advisor - The information on this channel is NOT financial advice.
These videos are designed purely for educational purposes and should serve as a starting spot to do your own research from.
The views on this channel are completely independent and in no way represent, nor are connected with any of the companies that may be discussed.
Nothing contained in this video should be construed as an offer, solicitation, or recommendation to buy or sell any investment or security, and is not designed to provide you with an investment strategy. The information provided should not be relied upon as the basis for making any purchase, sale or investment decision regarding any stock or asset.
These videos merely express my opinion, which is based on information obtained from sources believed to be accurate at the time of discussion.
ASX Investor is not liable for any loss caused, whether due to negligence or because of reliance on, the information provided directly or indirectly, in this video.